- Home
- ATXG vs RNAZ Comparison
ATXG vs RNAZ Comparison
Compare ATXG & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATXG | RNAZ |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 3.6M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ATXG | RNAZ |
|---|---|---|
| Price | $3.50 | $2.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 13.4K | ★ 41.0K |
| Earning Date | 02-13-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.22 | $1.83 |
| 52 Week High | $7.94 | $20.99 |
Technical Indicators
Market Signals| Indicator | ATXG | RNAZ |
|---|---|---|
| Relative Strength Index (RSI) | 44.06 | 25.76 |
| Support Level | $2.93 | N/A |
| Resistance Level | $5.17 | $6.15 |
| Average True Range (ATR) | 0.41 | 0.35 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 11.09 | 13.29 |
Price Performance
Historical ComparisonAbout ATXG Addentax Group Corp.
Addentax Group Corp is an investment holding company. The company through its operating subsidiaries functions in the following segments; Garment manufacturing; Logistics services and Consulting. It generates maximum revenue from the Logistics services segment which provides logistics services including storage, transportation, warehousing, handling, packaging, and order processing. It also provides customs declaration and tax clearance services to its customers who export goods overseas. Geographically, the company derives all of its revenue from China.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.